The U.S. Food and Drug Administration is experiencing significant leadership turnover as Jacqueline Corrigan-Curay, acting director of the Center for Drug Evaluation and Research (CDER), announced her upcoming retirement in July. This follows recent departures and administrative leave actions involving senior staff in the cell and gene therapy office, highlighting ongoing volatility within the agency. Observers express concern about potential impacts on regulatory continuity during a time of evolving approval standards and new program adoptions, particularly in advanced therapies. Leadership changes are occurring alongside broader HHS workforce reductions and policy recalibrations under FDA Commissioner Marty Makary.